Document is current
Any future updates will be listed below
-
Authors
Khatri, Vaseem M.
Mestres-Villanueva, Mariella A.
Daniel, Sierra
Yarlagadda, Sreenija
Doniparthi, Ajay
Upadhyay, Rituraj
Mills, Matthew N.
Oliver, Daniel E.
Yu, Hsiang-Hsuan Michael
Palmer, Joshua D.
Stover, Daniel G.
Williams, Nicole O.
Mahtani, Reshma L.
Ahluwalia, Manmeet S.
Soyano, Aixa E.
Soliman, Hatem H.
Han, Hyo S.
Kotecha, Rupesh
Beyer, Sasha J.
Ahmed, Kamran A.
- License Information
-
More Information
Article History
Received: 31 July 2025
Accepted: 30 August 2025
First Online: 30 September 2025
Declarations
:
: Hsiang-Hsuan Michael Yu has received speaker’s honoraria from BrainLab and is on the advisory boards of Novocure and Abbvie. Hatem Soliman serves as a consultant for Astrazeneca, Celgene, Novartis, PUMA, and Eisai and is on advisory boards for Novartis, Eisai, PUMA, Eli Lilly, Astrazeneca. Speaker fees for Merck. Hyo S. Han declares that she has received research funding from Abbvie, Arvinas, Pfizer, Seagen, Zymeworks and Quantum leap healthcare collaborative and on advisory boards for Pfizer and Arvinas. Kamran A. Ahmed has received research funding from Bristol-Myers Squibb, Eli Lilly, Gilead, and Genentech. Rupesh Kotecha has received honoraria from Accuray Inc., Elekta AB, ViewRay Inc., Novocure Inc., Elsevier Inc., Brainlab, Kazia Therapeutics, Castle Biosciences, and Ion Beam Applications and institutional research funding from Medtronic Inc., Blue Earth Diagnostics Ltd., Novocure Inc., GT Medical Technologies, AstraZeneca, Exelixis, ViewRay Inc., Brainlab, Cantex Pharmaceuticals, Kazia Therapeutics, and Ion Beam Applications. Reshma Mahtani is a consultant/advisor for Agendia, Amgen, Astra Zeneca, Daiichi, Eisai, Genentech, Gilead, Hologic, Lilly, Novartis, Pfizer, Puma, Sanofi, Sermonix, Stemline. Manmeet Ahluwalia has received consulting fees from Bayer, Kiyatec, Insightec, GSK, Xoft, Nuvation, SDP Oncology, Apollomics, Prelude, Janssen, Voyager Therapeutics, Viewray, Caris Lifesciences, Pyramid Biosciences, Varian Medical Systems, Cairn Therapeutics, Anheart Therapeutics, Theraguix, Menarini Ricerche, Sumitomo Pharma Oncology, Autem therapeutics, GT Medical Technologies, Allovir, EquilliumBio, QV Bioelectronics, grants to the institution from Seattle Genetics, is on the scientific advisory board of Modifi Biosciences, Bugworks, reports stock in Mimivax, Cytodyn, MedInnovate Advisors LLC, Trisalus Lifesciences, and is on the data safety monitoring committee for VBI Vaccines.
